國家衛生研究院 NHRI:Item 3990099045/8160
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 912524      線上人數 : 1206
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/8160


    題名: Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma
    作者: Tsai, HJ;Lin, SF;Chen, CC;Chen, TY;Su, WC;Hwang, WL;Lin, JC;Chiou, TJ;Kao, WY;Chiu, CF;Chang, YF;Chang, JS;Chang, MC;Su, IJ
    貢獻者: National Institute of Cancer Research;Division of Biostatistics and Bioinformatics;Division of Infectious Diseases
    摘要: PURPOSE: A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of front-line concurrent chemo-radiotherapy (CCRT) plus consolidation chemotherapy for patients with stage I/II nasal natural killer/T-cell lymphoma (NKTCL). PATIENTS AND METHODS: Patients with newly diagnosed, measurable stage I/II nasal NKTCL were eligible. The CCRT included 2 cycles of the DEP regimen (dexamethasone, etoposide plus cisplatin) every 4 weeks with concurrent 5,040 cGy radiation in 28 fractions for 5 weeks. Patients without disease progression after CCRT were subjected to 2 cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna and cisplatin every 4 weeks. The primary endpoint was tumor response rate and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov (NCT00292695). RESULTS: Thirty-three patients received CCRT and 29 patients received 2 cycles of consolidation DVIP after CCRT. Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81% (95% CI, 68-95%) and 63% (95% CI, 46-79%), respectively. The 2-year and 5-year progression-free survival rate for intention-to-treat population was 64% (95% CI, 47-80%) and 60% (95% CI, 39-73%), respectively; while the corresponding overall survival rate was 73% (95% CI, 57-88%) and 66% (95% CI, 50-83%), respectively. The most common treatment-related grade 3/4 adverse event was leukopenia (85%). CONCLUSION: Front-line CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL.
    日期: 2015-02
    關聯: European Journal of Haematology. 2015 Feb;94(2):130-137.
    Link to: http://dx.doi.org/10.1111/ejh.12405
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0902-4441&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000350099700007
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84922846170
    顯示於類別:[張書銘] 期刊論文
    [蔡慧珍] 期刊論文
    [陳主智] 期刊論文
    [蘇益仁(2002-2015)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB24957163.pdf147KbAdobe PDF619檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋